A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

• Status: Active, not recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets cancer cells, while leaving healthy cells unaffected.This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Treatments: Decitabine

Criteria

Inclusion Criteria:

• To be considered eligible for enrollment into this study, all of the following inclusion criteria must be met during the screening period:

• Documented AML by peripheral blood and bone marrow analyses meeting WHO criteria, excluding patients with acute promyelocytic leukemia (APL)

• Patients with AML refractory to primary induction chemotherapy, relapsed disease, or age ≥ 60 and not appropriate for standard cytotoxic therapy due to age, performance status, and/or adverse risk factors according to the treating physician

• Age ≥ 18 years

• Karnofsky performance status ≥ 50% or ECOG performance status 0-2

• Life expectancy ≥ 6 weeks

• Able to understand the investigational nature of this study and to provide written consent to participate in it

• Signed written IRB-approved Informed Consent document

• Adequate hepatic and renal function:

• serum bilirubin ≤ 1.5 X institutional ULN OR serum direct bilirubin ≤ 2 X institutional ULN

• serum ALT and AST ≤ 2.5 X institutional ULN

• serum alkaline phosphatase < 5 X institutional ULN

• serum creatinine ≤ 2.0 mg/dL

• corrected calcium level ≥ institutional LLN

• Negative pregnancy test in women of child-bearing potential

• Women and men of child-producing potential must agree to use effective contraceptive methods during the study period (including post-treatment observation period)

Exclusion Criteria:

• A patient will be considered not eligible for enrollment into this study if any of the following criteria are met during the screening period:

• Evidence of leukemic meningitis or other CNS involvement by leukemia

• Uncontrolled or poorly controlled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg) Note: an isolated reading that is not sustained will be permitted.

• Evidence of NYHA Class III or IV cardiac disease, or presence of unstable life-threatening arrhythmia, or history of myocardial infarction during the past 6 months

• Active bacterial, fungal, or viral infection requiring systemic treatment

• Known infection with HIV

• History or major surgery within 4 weeks before the first dose of study treatment, or not recovered from prior surgery

• Exposure to any other investigational agent at any time within 4 weeks before the first dose of study treatment

• Exposure to any other anti-leukemic therapy (except hydroxyurea, see Section 5.5.1) within 2 weeks before the first dose of study treatment

• Pregnant or lactating female

• Unwilling or unable to comply with the requirements of the study protocol